Clinical trials: Digestion Rate
Carcinoma, Hepatocellular
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer. Safety will be determined by laboratory and other evaluations.
- Trial name
- BASIL (NCT01204177)
- Testing
- BAY86-9766 MEK Inhibitor + Sorafenib
- Where
- 15 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 70 people
- Sponsor
- Bayer